Prediction of Acute Mountain Sickness using a Blood-Based Test
Annual rept. 20 Dec 2013-19 Dec 2014
COLORADO UNIV AURORA CO
Pagination or Media Count:
In the last year we have completed analysis of Phase II of the project. In Phase I we showed that an RNA-based gene signature from a sample taken at sea level could be used to successfully predict in 9 out of 10 individuals who went on to develop acute mountain sickness or who was AMS resistant. In Phase II, results suggest a completely independent sample was equally effective in predicting AMS susceptibility and resistance. These results were presented to the scientific leadership at Fort Detrick last spring. Under the advisement of that review process we have taken an expanded view of the data we are using for predicting AMS. Specifically, in addition to the data collected in this project for Phase I and Phase II, we will add several data sets to the overall analysis. New dataset 1 is analyses of an additional 70 samples from Phase I. These samples represent subjects who were not very sick or not very well, the middle of the road group. The hypothesis is that a very effective predictive test would predict those who might get very sick or not at all sick, but also those who feel only a little bit impaired by high altitude. New dataset 2 is from a companion project called AltitudeOmics where we have samples from sea level subjects exposed to very high altitude. All of these data will be analyzed in one integrated test to assess effectiveness. Our team of bioinformaticians is working together to realize these analyses in the following year.
- Medicine and Medical Research
- Stress Physiology